ArticleWorld journal of surgery2018
Lithium-Associated Hypercalcemia: Pathophysiology, Prevalence, Management.
Article in World journal of surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Lithium-associated hyperparathyroidism: a systematic review of prevalence and surgical outcomes.Langenbeck's archives of surgery · 2026Pooled it
- Atorvastatin lowers serum calcium levels in lithium-users: results from a randomized controlled trial.BMC endocrine disorders · 2022Trial
- Primary hyperparathyroidism unmasking after dienogest-altered estrogen dynamics: implications for calcium homeostasis.JCEM case reports · 2026Article
- Lithium and the Brain-Bone Axis: A Bridge between Osteoporosis and Alzheimer's Disease.Current osteoporosis reports · 2026Review
- Endocrine and Metabolic Challenges of Long-Term Lithium Therapy: Diagnostic and Management Considerations.Cureus · 2025Article
- Lithium-induced nephrogenic diabetes insipidus following improved medication compliance: a case report.Journal of medical case reports · 2025Article
- New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview.Pharmacological reviews · 2024Review
- Molecular and Clinical Spectrum of Primary Hyperparathyroidism.Endocrine reviews · 2023Article
- Lithium-Induced Hypercalcemia Presenting as Catatonia in a Patient With Schizoaffective Disorder.Cureus · 2023Article
- Lithium ameliorates Niemann-Pick C1 disease phenotypes by impeding STING/SREBP2 activation.iScience · 2023Article
- The use of Tablo continuous veno-venous haemodialysis to rapidly remove lithium in a patient with severe lithium toxicity.BMJ case reports · 2023Article
- Lithium: A Promising Anticancer Agent.Life (Basel, Switzerland) · 2023Review
- Two-way Road of Kidney and Hypercalcemia: A Narrative Review.Cardiovascular & hematological disorders drug targets · 2023Review
- Lithium induced hypercalcemia: an expert opinion and management algorithm.International journal of bipolar disorders · 2022Article
- Osteoprotegerin, Parathyroid Hormone and Vitamin D as Effective Factors on Serum-Urine Calcium Levels in Breast Cancer Patients.Archives of Razi Institute · 2022Article
- A Patient With Polyuria and Hypercalcemia.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022Article
- Relation of hyperparathyroidism and hypercalcemia to bipolar and psychotic disorders.Proceedings (Baylor University. Medical Center) · 2022Article
- Hypercalcemia, Acute Kidney Injury, and Metabolic Alkalosis.Case reports in nephrology · 2022Article
- Vitamin D in the time of the coronavirus (COVID-19) pandemic - a clinical review from a public health and public mental health perspective.Therapeutic advances in psychopharmacology · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLithium-associated hypercalcemia (LAH) is an ill-defined endocrinopathy. The aim of the present study was to determine the prevalence of hypercalcemia in a cohort of bipolar patients (BP) with and without concomitant lithium treatment and to study surgical outcomes for lithium-associated hyperparathyroidism.
methodsRetrospective data, including laboratory results, surgical outcomes and medications, were collected from 313 BP treated with lithium from two psychiatric outpatient units in central Sweden. In addition, data were collected from 148 BP without lithium and a randomly selected control population of 102 individuals. Logistic regression was used to compare odds of hypercalcemia in these respective populations.
resultsThe prevalence of lithium-associated hypercalcemia was 26%. Mild hypercalcemia was detected in 87 out of 563 study participants. The odds of hypercalcemia were significantly higher in BP with lithium treatment compared with BP unexposed to lithium (adjusted OR 13.45; 95% CI 3.09, 58.55; p = 0.001). No significant difference was detected between BP without lithium and control population (adjusted OR 2.40; 95% CI 0.38, 15.41; p = 0.355). Seven BP with lithium underwent surgery where an average of two parathyroid glands was removed. Parathyroid hyperplasia was present in four patients (57%) at the initial operation. One patient had persistent disease after the initial operation, and six patients had recurrent disease at follow-up time which was on average 10 years.
conclusionThe high prevalence of LAH justifies the regular monitoring of calcium homeostasis, particularly in high-risk groups. If surgery is necessary, bilateral neck exploration should be considered in patients on chronic lithium treatment. Prospective studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.